Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

N 6022

Next Previous
Drug Profile

N 6022

Alternative Names: N6022

Latest Information Update: 19 Feb 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator NitroMed
  • Developer Nivalis Therapeutics
  • Class Amides; Anti-inflammatories; Antiasthmatics; Carboxylic acids; Pyrroles; Small molecules
  • Mechanism of Action Alcohol dehydrogenase inhibitors; Glutathione-independent formaldehyde dehydrogenase inhibitors; Nitric oxide stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Acute asthma; Asthma; Chronic obstructive pulmonary disease; Inflammatory bowel diseases
  • Discontinued Cystic fibrosis

Most Recent Events

  • 25 Jul 2017 Alpine Immune Sciences has merged with Nivalis Therapeutics forming Alpine Immune Sciences
  • 31 May 2014 N30 Pharmaceuticals completes a phase Ib trial in Cystic fibrosis in USA (NCT01746784)
  • 20 Mar 2013 Preclinical pharmacodynamics data from a mouse model of asthma released by N30 Pharma

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top